|Day Low/High||15.85 / 16.40|
|52 Wk Low/High||14.40 / 30.35|
Investors in Lannett Co., Inc. saw new options begin trading this week, for the April 20th expiration.
Investors in Lannett Co., Inc. saw new options become available this week, for the September 21st expiration.
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Lannett Company, Inc.
Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating whether certain directors and officers of Lannett Company, Inc.
In recent trading, shares of Lannett Co., Inc. have crossed above the average analyst 12-month target price of $26.30, changing hands for $27.50/share.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Lannett Co., Inc. , where a total of 29,266 contracts have traded so far, representing approximately 2.9 million underlying shares.
State attorneys general led by Connecticut's George Jepsen said Tuesday that were planning to include Mylan president Rajiv Malik and Emcure Pharmaceuticals Ltd. executive Satish Mehta in an expanded complaint in the federal generic drug antitrust lawsuit.
In trading on Monday, shares of Lannett Co., Inc. crossed above their 200 day moving average of $20.67, changing hands as high as $20.90 per share.
Here's what you need to know now for Wednesday, Sept. 27.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Lannett Co., Inc. , where a total of 4,873 contracts have traded so far, representing approximately 487,300 underlying shares.
Cellect Biomd was up after securing orphan drug status for its transplant anti-rejection drug.
Teva is 'in no shape' to be making acquisitions while Mylan is 'still pretty leveraged,' says Oppenheimer analyst Derek Archila.
It is just not going to get better anytime soon.
Teva's stock is crumbling as another analyst slams it with a downgrade.
Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.
In trading on Friday, shares of Lannett Co., Inc. crossed above their 200 day moving average of $22.22, changing hands as high as $22.70 per share.
Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..
Investors considering a purchase of Lannett Co., Inc. stock, but cautious about paying the going market price of $20.00/share, might benefit from considering selling puts among the alternative strategies at their disposal.
The addition of Perrigo to the list of generics makers under investigation is more bad news for a sector already under pressure from low prices.
In trading on Wednesday, shares of Lannett Co., Inc. crossed below their 200 day moving average of $24.97, changing hands as low as $21.60 per share.
The investigation is in relation to drug pricing in the pharmaceutical industry.
These heavily shorted stocks could get squeezed sharply higher if they report positive earnings this week.
In trading on Monday, shares of Lannett Co., Inc. crossed above their 200 day moving average of $24.95, changing hands as high as $26.30 per share.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.